Emergent BioSolutions Reports First Quarter 2019 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31,...
Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2019, recent business...
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus...
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909...
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term,...
Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31,...
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019....
Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2018,...
Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr. Kramer currently serves as Emergent’s president and COO....
Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Emergent BioSolutions Inc. (NYSE: EBS) today announced selected preliminary unaudited 2018 financial results and its financial forecast for...
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the...
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration (FDA) for potential emergency use of NuThrax™ (anthrax vaccine...